Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Tremfya showed greater persistence in bio-naïve and ...

Guselkumab significantly and rapidly improved severe scalp psoriasis, itch, and patient-reported health-related quality of life outcomes in people of color. Guselkumab shows rapid and significant ...

Please provide your email address to receive an email when new articles are posted on . At week 16, 49.4% of the tildrakizumab group achieved clearance or near clearance of their scalp psoriasis vs. 7 ...

Patients treated with ILUMYA demonstrated a significantly higher rate of 75% improvement from baseline in the Nail Psoriasis Severity Index (mNAPSI 75) at Week 28 (25.5% mNAPSI 75 response rate vs.

Working on fast cars has been Rogelio "Al" Castro's lifelong passion. Now, in retirement, he loves to take his grandkids to the speedway and tell them what it was like when he worked in the pit - the ...

TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Reader's DigestHome Remedies for Eczema and Psoriasis ReliefSave money on expensive skin care treatments and try these homemade remedies first. Plaque psoriasis is a skin disease that causes raised ...